A Phase 1, Open Label Study of ABT-869 in Combination With Tarceva in Subjects With Advanced Non-Hematologic Malignancy.

Trial Profile

A Phase 1, Open Label Study of ABT-869 in Combination With Tarceva in Subjects With Advanced Non-Hematologic Malignancy.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Linifanib (Primary) ; Erlotinib
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 28 Jan 2009 Actual initiation date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 28 Jan 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 28 Jan 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 28-1-2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top